Market Overview

RBC Optimistic on Regeneron Following Lower Sales by Novartis' Lucentis


RBC Capital Markets analyst Adnan Butt is optimistic on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) following lower sales outside the US by competing Novartis AG (NYSE: NVS) drug Lucentis.

Lucentis, is a ranibizumab injection for the treatment of wet age-related macular degeneration (AMD), macular edema following retinal vein occlusion. Lucentis is sold in the US via Genentech, and is marketed outside the U.S. by Novartis.

In Novartis' interim financial report, the company reported that Lucentis yielded $620 million (USD) in the first quarter 2014, up 6 percent cc. In the first quarter 2013, Novartis reported that Lucentis made $596 million (USD), up 4 percent cc.

According to RBC, the decrease in Lucenta sales underscores potential market share loss to Regeneron's Eyelea. Adnan Butt added that Lucentis growth in non-wet AMD indications outside the U.S. suggests that there is room for Eyelea to expand as it secures other approvals, including diabetic macular edema (DME). The analyst expects to Eyelea to capture more than half of the branded market share in the long-term.

Regeneron's Eyelea has a Pdufa date in DME on August 18. Regeneron reports first quarter results pre-market on May 8, 2014.

Shares of Regeneron closed at $293.43, down 3.18 percent for the day.

Latest Ratings for REGN

Nov 2020Morgan StanleyMaintainsEqual-Weight
Nov 2020Credit SuisseMaintainsOutperform
Nov 2020SVB LeerinkMaintainsOutperform

View More Analyst Ratings for REGN
View the Latest Analyst Ratings


Related Articles (REGN)

View Comments and Join the Discussion!

Posted-In: Adnan Butt Eyelea Genentech Lucentis RBC Capital MarketsAnalyst Color Reiteration Analyst Ratings

Latest Ratings

PMTB of A SecuritiesMaintains18.5
IVRB of A SecuritiesMaintains3.0
EFCB of A SecuritiesMaintains15.5
NYMTB of A SecuritiesMaintains3.5
NLYB of A SecuritiesMaintains8.5
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at